Johnny Hu, PhD

As a principal at Menlo Ventures, Johnny invests at the intersection of AI and life sciences and healthcare. He focuses on novel therapeutics and new technologies for improving medical outcomes and is a Board Director at Vilya Therapeutics, Board Observer at Chai Discovery, and Founding CEO and Chair of the Board at Aurora Therapeutics.

Prior to Menlo, Johnny was a vice president at Longitude Capital, where he made several investments in early-stage biotech companies. He was a board observer at Lexeo Therapeutics, Endeavor Biomedicines,  on the investment team for Amunix Pharmaceuticals (acquired by Sanofi for >$1bn).

Johnny received his Ph.D. from Harvard University as a National Defense Science and Engineering Graduate Fellow and a National Science Foundation Graduate Research Fellow. While completing his Ph.D., Johnny helped develop gene editing technologies that were licensed by companies such as Editas Medicine (NASDAQ: EDIT) and Beam Therapeutics (NASDAQ: BEAM). He also holds an M.Phil. from the University of Cambridge, where he was a Gates Cambridge Scholar, and an A.B., summa cum laude, in Chemical and Physical Biology from Harvard.